CompletedPhase 2

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

United States32 participantsStarted 2011-08

Plain-language summary

This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.

Who can participate

Age range10 Years – 21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

INCLUSION CRITERIA * Age 10 to 21 years * Suspected or confirmed diagnosis of a bone sarcoma or osteomyelitis * Informed consent with assent as appropriate. EXCLUSION CRITERIA * Contraindication to MRI * Presence of metal implants * Need for sedation or anesthesia * Claustrophobia * Hemosiderosis or hemochromatosis * History of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the study * Females who are pregnancy or nursing

What they're measuring

T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects

Timeframe: 24 hours

Trial details

NCT IDNCT01336803

SponsorHeike E Daldrup-Link

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-07

Results submitted2019-05-03

View on ClinicalTrials.gov More Bone Cancer trials